ConductScience.org, home

Paper · 42360909

FGF18 mediates fibroblast-leukemia cross talk to promote acute myeloid leukemia progression.

Zhang W and 12 others. Blood, 2026. Cited by 0 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. FGF18 mediates fibroblast-leukemia cross talk to promote acute myeloid leukemia progression. Papers, record 42360909. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42360909

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
FGF18 mediates fibroblast-leukemia cross talk to promote acute myeloid leukemia progression.
PubMed
Journal
Blood
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-10-28
PubMed

Authors13

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zhang WWuju
2Ye ZZhixin
3Zhou XXuan
4Xiong PPengfei
5Pan YYating
6Qiu JJielei
7Li MMeifang
8Shen JJinglinghttps://orcid.org/0000-0003-0177-1985
9Li YYuhuahttps://orcid.org/0000-0002-0982-6680
10Lu YYao

1 to 10 of 13Source PubMed

See all 13 authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Leukemia, Myeloid, AcuteMajor topic
Fibroblast Growth FactorsMajor topic
FibroblastsMajor topic
Animals
Humans
Mice
Disease Progression
Receptor, Fibroblast Growth Factor, Type 3
Signal Transduction
Tumor Microenvironment
TOR Serine-Threonine Kinases
Interleukin-6

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in42,821,300Systems reboot: a niche-based approach to AML.https://conductscience.org/library/papers/42821300

Source PubMed

References59

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130,082,912FGF18, a prominent player in FGF signaling, promotes gastric tumorigenesis through autocrine manner and is negatively regulated by miR-590-5p.Oncogene2019https://conductscience.org/library/papers/30082912PubMed
238,228,679Inflammatory recruitment of healthy hematopoietic stem and progenitor cells in the acute myeloid leukemia niche.Leukemia2024https://conductscience.org/library/papers/38228679PubMed
336,574,771Decoding m6A RNA methylome identifies PRMT6-regulated lipid transport promoting AML stem cell maintenance.Cell Stem Cell2023https://conductscience.org/library/papers/36574771PubMed
439,480,488Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels.J Clin Invest2024https://conductscience.org/library/papers/39480488PubMed
540,663,784The acute myeloid leukemia microenvironment impairs neutrophil maturation and function through NF-κB signaling.Blood2025https://conductscience.org/library/papers/40663784PubMed
637,768,887FGFR3 Alterations in Bladder Cancer Stimulate Serine Synthesis to Induce Immune-Inert Macrophages That Suppress T-cell Recruitment and Activation.Cancer Res2023https://conductscience.org/library/papers/37768887PubMed
737,001,042TREM2 acts as a receptor for IL-34 to suppress acute myeloid leukemia in mice.Blood2023https://conductscience.org/library/papers/37001042PubMed
840,796,662A STUB1-CHIC2 complex inhibits CD8+ T cells to restrain tumor immunity.Nat Immunol2025https://conductscience.org/library/papers/40796662PubMed
936,550,214Microenvironmental CXCL12 deletion enhances Flt3-ITD acute myeloid leukemia stem cell response to therapy by reducing p38 MAPK signaling.Leukemia2023https://conductscience.org/library/papers/36550214PubMed
1029,563,517Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients.Blood Cancer J2018https://conductscience.org/library/papers/29563517PubMed

Cited by0

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.

None in this release.

Genes8

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42360909

GET https://conductscience.org/api/papers/v1/42360909/references?page=2